Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke.
There is currently a stark therapeutic void in the treatment of evolving stroke. Although P-selectin is rapidly expressed by hypoxic endothelial cells in vitro, the functional significance of P-selectin expression in stroke remains unexplored. In order to identify the pathophysiological consequences of P-selectin expression and to identify P-selectin blockade as a potential new approach for the treatment of stroke, experiments were performed using a murine model of focal cerebral ischemia and reperfusion. Early P-selectin expression in the postischemic cerebral cortex was demonstrated by the specific accumulation of radiolabeled anti-murine P-selectin IgG, with the increased P-selectin expression localized to the ipsilateral cerebral microvascular endothelial cells by immunohistochemistry. In experiments designed to test the functional significance of increased P-selectin expression in stroke, neutrophil accumulation in the ischemic cortex of mice expressing the P-selectin gene (PS +/+) was demonstrated to be significantly greater than that in homozygous P-selectin-null mice (PS -/-). Reduced neutrophil influx was accompanied by greater postischemic cerebral reflow (measured by laser Doppler) in the PS -/- mice. In addition, PS -/- mice demonstrated smaller infarct volumes (5-fold reduction, P<.05) and improved survival compared with PS +/+ mice (88% versus 44%, P<.05). Functional blockade of P-selectin in PS +/+ mice using a monoclonal antibody directed against murine P-selectin also improved early reflow and stroke outcome compared with control mice, with reduced cerebral infarction volumes noted even when the blocking antibody was administered after occlusion of the middle cerebral artery. These data are the first to demonstrate a pathophysiological role for P-selectin in stroke and suggest that P-selectin blockade may represent a new therapeutic target in the treatment of stroke.
Connolly
E S
ES
Department of Neurosurgery, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.
Winfree
C J
CJ
Prestigiacomo
C J
CJ
Kim
S C
SC
Choudhri
T F
TF
Hoh
B L
BL
Naka
Y
Y
Solomon
R A
RA
Pinsky
D J
DJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001930:Brain Injuries / Q000209:etiology* / Q000235:genetics / Q000503:physiopathology; D002545:Brain Ischemia / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D002465:Cell Movement; D002540:Cerebral Cortex / Q000098:blood supply / Q000503:physiopathology; D002561:Cerebrovascular Disorders / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D004195:Disease Models, Animal; D005260:Female; D015870:Gene Expression; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009504:Neutrophils / Q000473:pathology / Q000502:physiology; D019007:P-Selectin / Q000235:genetics* / Q000276:immunology / Q000502:physiology*; D015427:Reperfusion Injury / Q000235:genetics / Q000503:physiopathology / Q000628:therapy
D000911:Antibodies, Monoclonal; D019007:P-Selectin